Zimmer Biomet (ZBH) Q1 2025: Paragon 28 Adds 270bps Growth, Offsetting Tariff and Margin Headwinds
Zimmer Biomet’s Q1 2025 showcased resilient execution on new product cycles and integration of Paragon 28, with management reaffirming organic growth targets despite tariff headwinds and margin compression. Portfolio diversification and operational discipline are now essential levers as the company navigates pricing normalization, ASC channel shifts, and a volatile regulatory environment. Second-half product launches and integration outcomes will be pivotal for sustaining above-market growth.
Summary
- Paragon 28 Integration Drives Diversification: Foot and ankle acquisition now contributes more to growth than legacy hip business.
- Margin and Tariff Pressures Managed with Operational Levers: FX tailwinds, cost controls, and pricing discipline offset macro headwinds.
- Second-Half Product Launches Will Test Execution: New knees and robotics expected to accelerate growth as U.S. channel resets.
Performance Analysis
Zimmer Biomet’s Q1 2025 results reflected measured growth with sales up 2.3% constant currency and a clear split between U.S. and international performance. The U.S. saw 1.3% growth, led by nearly 4% gains in hips and SET (Surgical, Extremities and Trauma), while knees lagged at just 0.2%. International markets outperformed, with 3.7% growth, driven by mid-single-digit expansion in knees and high-single-digit SET gains. The company highlighted that half of new Z1 hip users in the U.S. are competitive conversions, signaling real share capture in a mature market.
Margin compression was evident, with adjusted operating margin down to 26.2% and gross margin at 71.5%, both lower year-over-year but in line with expectations. Tariff impacts and upfront investments in new products weighed on profitability, offset by FX tailwinds and disciplined cost management. Free cash flow remained robust at $279 million, aided by a significant reduction in inventory days on hand—now at 370, down nearly 50 days year-over-year.
- SET Outpaces Core Joints: SET segment grew 4.9% and now surpasses hips in scale post-Paragon 28.
- Inventory Efficiency Unlocks Cash: Nearly 47-day reduction in days on hand signals improved working capital discipline.
- Tariff Headwind Quantified, Not Catastrophic: $60–80 million impact in 2025, mostly back-half loaded, but fully offset in guidance.
Despite margin pressure and a modest EPS guide-down, Zimmer Biomet’s results reinforce its ability to flex operational levers and sustain investment in innovation while absorbing external shocks.
Executive Commentary
"We are maintaining our full-year organic constant currency revenue growth expectations of 3% to 5%, which excludes contribution from the Paragon 28 acquisition. We anticipate Paragon 28 to contribute 270 basis points to sales growth in 2025."
Ron Tornos, President and CEO
"Our working capital initiatives targeted towards inventory reduction continue to pay off, as we reduced days on hand by almost 47 days compared to Q1 2024, ending at approximately 370 days of inventory on hand."
Sukhiya Patia, Chief Financial Officer
Strategic Positioning
1. Paragon 28 Integration and Portfolio Diversification
The Paragon 28 acquisition, foot and ankle solutions, is now fully closed and integrated, with leadership and field sales teams retained. This move immediately diversifies Zimmer Biomet’s revenue base, making SET the company’s second-largest segment and aligning with a strategic pivot toward faster-growing markets. Management emphasized minimal disruption and a focus on preserving Paragon’s innovation engine, with the Denver design center remaining independent. This acquisition is a clear signal that inorganic growth, especially in ASC (Ambulatory Surgery Center) and extremities, is the new capital allocation priority.
2. U.S. Commercial Reset and Channel Optimization
U.S. knees remain a weak spot, but management is pushing a “faster” evolution in sales leadership, territory realignment, and incentive structures. The company is expanding specialized field teams in SET and robotics, with a specific focus on ASC channel growth—now over 20% of U.S. sales and expected to rise sharply. Leadership changes and commercial execution are positioned as the key to unlocking growth in lagging U.S. knees, with second-half launches seen as the inflection point.
3. Innovation Pipeline and Patient Engagement
Zimmer Biomet’s “Magnificent Seven” product cycle, featuring Z1 hip, Persona Osseotide cementless knee, Oxford Partial cementless knee, and OrthoGrid AI guidance, is now driving both share capture and premium pricing. The company is also launching direct-to-patient awareness campaigns (notably the “You’ll Be Back” campaign with Arnold Schwarzenegger) to address underpenetration in osteoarthritis treatment. Smart implants, AI-driven surgical tools, and infection prevention technologies (such as iodine-coated implants) are positioned as future growth levers, with a pathway to U.S. approval underway.
4. Margin Management and Pricing Discipline
Margin pressure from tariffs and new product investments is being actively managed through FX tailwinds, discretionary cost controls, and supply chain optimization. Pricing, while normalizing after several quarters of tailwinds, is expected to be flat for the year, with management citing improved competitive discipline and internal pricing governance. Opportunistic price increases are being considered in capital and surgical businesses, not core recon, to offset input cost volatility.
5. M&A Appetite Remains High
Despite the Paragon 28 deal and tariff drag, Zimmer Biomet maintains a strong balance sheet and leverage in the low-to-mid threes. Management signaled continued interest in tuck-in acquisitions, particularly in ASC, SET, and enabling technologies, with a focus on maintaining EPS dilution below 3% in year one and neutral by year two. Expansion into adjacencies and data-driven offerings is on the horizon, but core musculoskeletal health remains the near-term focus.
Key Considerations
This quarter marks a strategic transition for Zimmer Biomet, as it balances near-term headwinds with long-term growth bets in new segments and technologies. The integration of Paragon 28 and the ramp of new knees and robotics will determine whether the company can sustain above-market growth and margin recovery in a challenging environment.
Key Considerations:
- ASC Channel Acceleration: Over 20% of U.S. sales now come from ASCs, with management expecting this to rise to 40–60% within five years.
- Real Share Gains in Hips: 50% of new Z1 hip users are competitive conversions, validating the product cycle strategy.
- Inventory Turns as Cash Flow Lever: Reduction in days on hand is unlocking working capital and funding growth investments.
- Tariff Mitigation Relies on Sourcing and Cost Controls: Country-of-origin optimization and discretionary spend cuts are blunting the impact of global tariffs for now.
- Second-Half Product Uptake Is Critical: The inflection in knees and SET hinges on successful commercial execution and supply chain readiness.
Risks
Tariff volatility and regulatory uncertainty remain key risks, with the potential for higher-than-expected cost drag in 2026 as annualization and inventory capitalization effects roll through. U.S. knees execution is still unproven, and pricing normalization may limit upside from new launches. Competitive pressure, especially in robotics, and potential delays in innovation adoption could challenge top-line momentum.
Forward Outlook
For Q2 2025, Zimmer Biomet guided to:
- Organic constant currency growth slightly higher than Q1’s 2.3% (excluding days adjustment).
- Tariff impact to be minimal in Q2, with over half of the full-year impact anticipated in Q4.
For full-year 2025, management maintained guidance:
- Organic constant currency revenue growth of 3%–5% (excluding Paragon 28).
- Paragon 28 to add 270bps to reported sales growth (total 5.7%–8.2%).
- Adjusted EPS of $7.90–$8.10 and free cash flow of $750–$850 million.
Management emphasized confidence in new product execution and ongoing cost mitigation to offset macro headwinds, with a second-half acceleration expected as product launches and channel resets take hold.
- Second-half growth and margin recovery depend on successful ramp of knees, SET, and Paragon 28 integration.
- Tariff impact not expected to be a run rate for 2026, but risk remains for higher cost drag next year.
Takeaways
Zimmer Biomet delivered a strategically significant quarter, demonstrating the ability to absorb macro shocks while accelerating its shift toward faster-growth and higher-margin businesses.
- Portfolio Shift Is Material: SET now surpasses hips in revenue, validating the diversification strategy and M&A focus.
- Tariff Risk Is Managed, Not Eliminated: Operational levers and FX tailwinds provide near-term relief, but 2026 cost pressure remains a watchpoint.
- Execution on Second-Half Launches Will Define Trajectory: Investors should closely monitor the pace of knee adoption, ASC penetration, and Paragon 28 synergy realization as leading indicators of sustainable outperformance.
Conclusion
Zimmer Biomet’s Q1 2025 results reinforce its evolving business model, with real progress in portfolio diversification, operational discipline, and product innovation. The company’s ability to manage through tariff and margin headwinds while maintaining growth guidance will be tested by the scale and speed of second-half launches and integration execution.
Industry Read-Through
Zimmer Biomet’s quarter highlights several sector-wide themes: Portfolio diversification and scale M&A are becoming critical as legacy joints growth matures and ASC migration accelerates. Tariff mitigation and sourcing agility will be a differentiator for medtech companies with global supply chains. The normalization of pricing tailwinds signals a more competitive environment, putting a premium on commercial execution and innovation. Robotics adoption and digital enablement are now table stakes, with incremental share gains hinging on data, AI, and patient engagement strategies. The industry should expect continued capital allocation toward tuck-in deals in extremities, ASC, and enabling technologies as the growth playbook for the next cycle.